Sp1131

MECHANISMS OF CENTRAL SENSITIZATION IN POST-INFLAMMATORY VISCERAL PAIN

Date
May 9, 2023
Explore related products in the following collection:

Society: AGA

Visceral pain is a leading cause of disability worldwide, affecting 20% of the population. Increased sensitivity to normal innocuous stimuli in the intestine is a hallmark of many organic and functional gastrointestinal disorders. A better understanding of the mechanisms associated with visceral hypersensitivity whether they include peripheral (eg microbiome-diet) or central inputs is necessary and critical in order to be able to treat patients. This workshop will present and discuss recent advances in our understanding of the factors that stimulate nociceptors of the intestine, and further central sensitization. Among the mechanisms that will be discussed are microbial factors, epithelial factors, immune mediators, and neuro-immune interactions, all studied in the setting of models, but also in patients' cohorts. This workshop is timely since cohorts of IBD patients are on-going aiming at phenotyping pain in such patients, and further identifying mechanisms associated with abdominal pain. Recent calls from national and international charities are supporting research on visceral pain, recognizing chronic pain as a priority research area. The implication of findings and potential treatments discussed should be of interest to a broad array of researchers from industrial, clinical and basic research background.

Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…